SCHEMBL7104945

SCHEMBL7104945

Nc1ccc(S(=O)(=O)N2CCNCC2)c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.57
NFKB1 P19838 3/20 0.57
CYP1A2 P05177 3/20 0.57
TP53 P04637 2/20 0.57
CYP2D6 P10635 2/20 0.57
MAPK1 P28482 2/20 0.57
MYLK Q15746 2/20 0.57
MEN1 O00255 1/20 0.57
CYP2C9 P11712 1/20 0.57
KMT2A Q03164 1/20 0.57
ROCK1 Q13464 3/20 0.56
ROCK2 O75116 3/20 0.56
PRKCE Q02156 2/20 0.56
PRKCD Q05655 2/20 0.56
PRKD1 Q15139 2/20 0.56
PRKX P51817 1/20 0.56
LMNA P02545 3/20 0.56
TSHR P16473 3/20 0.56
GMNN O75496 2/20 0.56
MAPT P10636 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25532 0.89 POLB (0.58) CYP3A4MEN1CYP2C9KMT2ALMNA
SCHEMBL10037158 0.81 USP2 (0.51) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL2960623 0.78 MEN1 (0.71) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL5650140 0.75 KMT2A (0.77) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL31033068 0.75 KMT2A (0.77) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL7837749 0.75 SMN1; SMN2 (0.77) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL18138090 0.74 KMT2A (0.75) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL19856464 0.74 KMT2A (0.75) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL29764343 0.74 CYP3A4 (0.55) CYP3A4NFKB1CYP1A2TP53CYP2D6
SCHEMBL9281354 0.74 CYP3A4 (0.73) CYP3A4NFKB1CYP1A2TP53CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030068275-A1 Coordination complexes for detecting analytes, and methods of making and using the same MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2003-04-10 US disclosed
EP-0836597-A1 N-SUBSTITUTED PIPERAZINE NONOATES THE UNITED STATES OF AMERICA (US) 1998-04-22 EP disclosed
US-5721365-A N-substituted piperazine NONOates HEALTH AND HUMAN SERVICES, DEPARTMENT OF, UNITED STATES, AS REPRESENTED BY ITS SECRETARY 1998-02-24 US disclosed
WO-1996040665-A1 N-SUBSTITUTED PIPERAZINE NONOATES THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030068275-A1 Coordination complexes for detecting analytes, and methods of making and using the same SPR, CACYBP, CA13 CYP3A4 483/4885NFKB1 1942/4885CYP1A2 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.